Jellagen announce significant collaboration with a major global regenerative and medical technology company.02/02/22
Jellagen is proud to announce a significant funded research and development collaboration with a major global regenerative and medical technology company. This product development partnership will investigate Jellagen’s Collagen Type 0 as the core collagen biomaterial for several, ground-breaking new solutions in regenerative medicine.
Preclinical in vivo results have proven Collagen Type 0 to be superior to its mammalian counterparts in medical application – a paradigm shift in collagen chemistry with the potential to regenerate tissue in multiple indications.
Starting in January 2022, and extending for up to four-years contingent on results, this exciting initiative will develop multiple Collagen Type 0 product formulations for use across multiple applications in the treatment of tissue repair.
“We are delighted to have secured such a significant collaboration with one of the world’s leading medical technology companies”, commented Thomas-Paul Descamps, Jellagen’s Chief Executive Officer. “This commitment will help accelerate our ambition to harness the unique properties of Collagen Type 0 for tissue engineering and transform regenerative medicine.”